Skip to content

Cerevance

  • Platform
  • Tissue Collection
  • Pipeline
  • Team
    • Leadership
    • Advisors
    • Board
    • Investors
  • News
    • Press Releases
    • Media Coverage
  • Careers
  • Contact

News

Press Releases

August 9, 2022

Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease

June 16, 2022

Cerevance to Present During the 5th Annual LSX World Congress USA

June 8, 2022

Cerevance to Participate in Panel Discussion During the 2022 BIO International Convention

April 19, 2022

Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases

March 31, 2022

Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism

January 25, 2022

Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766

September 8, 2021

Neuroscience Drug Development Veteran Mike Poole, M.D., FACP, to Join Cerevance Board of Directors

February 10, 2021

Cerevance Appoints Naidong Ye, Ph.D. as Vice President and Head of Chemistry, Manufacturing and Controls

February 1, 2021

Cerevance Appoints Carrie Ann Cook as Chief Business Officer

December 8, 2020

Cerevance Appoints David Lubner to Board of Directors

  • 1
  • 2
  • 3

View Media Coverage

Cerevance
  • Platform
  • Tissue Collection
  • Pipeline
  • Team
  • News
  • Careers
  • Contact
Copyright Cerevance 2022